IL6 and familial pancreatic carcinoma: Targeted therapy against IL-6 has shown promising results in mouse models and in vitro cell lines of various cancers, by dampening the IL-6/JAK/STAT3 signaling pathway in gastric cancer [167], ovarian cancer [107, 112, 168–170], and pancreatic cancer [171].